Avita Medical Receives Additional AFIRM Funding In ReCell Study

Published: 28-Jan-2010

Avita Medical has been awarded an additional $450,000 from the US Armed Forces Institute of Regenerative Medicine (AFIRM), to expedite approval of the company’s ReCell Autologous Spray On Skin in the US market. The fund is in addition to the $1.45m granted to Avita by AFIRM in May 2009.

The additional funding follows recognition of the ReCell regenerative technology as a crucial technology in the Department of Defense’s AFIRM program.

Avita was awarded the additional grant following a review of the program by AFIRM project leaders. The AFIRM program, established in April 2008, is dedicated to bring ‘transformational technologies’ in regenerative medicine to wounded soldiers, by developing clinical therapies and advanced treatment options.

William Dolphin, CEO OF Avita Medical, said that the original grant and the additional funding is a substantial endorsement of ReCell.

Mr Dolphin added: “We greatly appreciate the continued support of AFIRM. The Department of Defense has recognized the major benefits which ReCell provides to patients and surgeons with improved outcomes and decreased morbidity. It should also result in significant reduction in costs to the healthcare system and third party payers with reduced hospitalization times and ongoing treatment costs.

“We and the AFIRM program leaders are confident that ReCell will redefine the clinical treatment of burns, scar remodeling and other skin defects and injuries.”

Tell your friend about this article